NO933171D0 - Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommer - Google Patents
Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommerInfo
- Publication number
- NO933171D0 NO933171D0 NO933171A NO933171A NO933171D0 NO 933171 D0 NO933171 D0 NO 933171D0 NO 933171 A NO933171 A NO 933171A NO 933171 A NO933171 A NO 933171A NO 933171 D0 NO933171 D0 NO 933171D0
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- cell surface
- surface receptors
- viral diseases
- molecules targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66576291A | 1991-03-07 | 1991-03-07 | |
| PCT/US1992/001705 WO1992015318A1 (en) | 1991-03-07 | 1992-03-05 | Use of cell surface receptor targeted molecules for the treatment of viral diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO933171D0 true NO933171D0 (no) | 1993-09-06 |
| NO933171L NO933171L (no) | 1993-11-11 |
Family
ID=24671481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO933171A NO933171L (no) | 1991-03-07 | 1993-09-06 | Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6074636A (no) |
| EP (1) | EP0721340A1 (no) |
| JP (1) | JPH06508821A (no) |
| AU (1) | AU1643692A (no) |
| CA (1) | CA2104958A1 (no) |
| FI (1) | FI933909A0 (no) |
| NO (1) | NO933171L (no) |
| WO (1) | WO1992015318A1 (no) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| AU2596600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Modified hiv env polypeptides |
| US6602705B1 (en) * | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| CA2369762A1 (en) * | 1999-04-16 | 2000-10-26 | Peter P. Lee | A method for improving the half-life of soluble viral-specific ligands on mucosal membranes |
| EP1418936A2 (en) * | 2001-05-09 | 2004-05-19 | Alk-Abell A/S | Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. |
| US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| WO2003004657A1 (en) * | 2001-07-05 | 2003-01-16 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| WO2003020876A2 (en) * | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| AU2003219730A1 (en) * | 2002-02-07 | 2003-09-02 | Massachusetts Institute Of Technology | Anti-pathogen treatements |
| ES2401136T3 (es) | 2002-11-15 | 2013-04-17 | Genmab A/S | Anticuerpos monoclonales humanos contra CD25 |
| AU2008254578B2 (en) * | 2007-05-21 | 2013-06-06 | Alderbio Holdings Llc | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8404235B2 (en) * | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| SG183742A1 (en) | 2007-05-21 | 2012-09-27 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| WO2011066369A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to raise albumin and/or lower crp |
| US9304134B2 (en) | 2010-11-23 | 2016-04-05 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of anemia |
| US20160108122A1 (en) * | 2013-05-23 | 2016-04-21 | Idac Theranostics, Inc. | Therapeutic or prophylactic agent for immunodeficiency virus infection |
| US20220062390A1 (en) | 2020-08-26 | 2022-03-03 | Dr. Reddy's Laboratories Sa | Methods of treating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340494C (en) * | 1988-05-19 | 1999-04-13 | The Beth Israel Hospital Association And Brigham And Women's Hospital | Induction of tolerance to a foreign antigen |
| ZA902949B (en) * | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| WO1991001004A1 (en) * | 1989-07-06 | 1991-01-24 | Seragen, Inc. | Hybrid molecules |
| CA2086679A1 (en) * | 1990-07-05 | 1992-01-06 | Hermanus A. M. Verheul | Receptor directed-toxin conjugates |
-
1992
- 1992-03-05 EP EP92908403A patent/EP0721340A1/en not_active Withdrawn
- 1992-03-05 AU AU16436/92A patent/AU1643692A/en not_active Abandoned
- 1992-03-05 CA CA002104958A patent/CA2104958A1/en not_active Abandoned
- 1992-03-05 JP JP4508253A patent/JPH06508821A/ja active Pending
- 1992-03-05 WO PCT/US1992/001705 patent/WO1992015318A1/en not_active Application Discontinuation
-
1993
- 1993-09-06 NO NO933171A patent/NO933171L/no unknown
- 1993-09-07 FI FI933909A patent/FI933909A0/fi not_active Application Discontinuation
-
1995
- 1995-06-05 US US08/465,541 patent/US6074636A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU1643692A (en) | 1992-10-06 |
| US6074636A (en) | 2000-06-13 |
| CA2104958A1 (en) | 1992-09-08 |
| EP0721340A4 (en) | 1995-08-11 |
| NO933171L (no) | 1993-11-11 |
| FI933909A0 (fi) | 1993-09-07 |
| EP0721340A1 (en) | 1996-07-17 |
| WO1992015318A1 (en) | 1992-09-17 |
| JPH06508821A (ja) | 1994-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO933171D0 (no) | Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommer | |
| FI944034L (fi) | Kertakäyttöinhalaattori | |
| DE59304238D1 (de) | Wegwerfwindel | |
| DE59304237D1 (de) | Wegwerfwindel | |
| DE59308565D1 (de) | Wegwerfwindel | |
| NO924461D0 (no) | Dipyridamol for behandling av proliferaktive sykdommer | |
| FI943805L (fi) | Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon | |
| DK165045C (da) | Koerestol med sekshjulsstel | |
| DE69325373D1 (de) | Therapeutische ultraschallzahnbürste | |
| NO306850B1 (no) | Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom | |
| FI971568A0 (fi) | Menetelmä resistenttien kasvainten hoitamiseksi | |
| IT9067866A0 (it) | Dispositivo per annullare la curvatura di fogli | |
| EP0730609A4 (en) | Recombinant il4 antibodies useful in treatment of il4 mediated disorders | |
| FI962370A0 (fi) | Laite tissuen valmistamiseksi | |
| FI933350L (fi) | Foerfarande och anordning foer maolterapi | |
| TR25057A (tr) | Aritim camurlarinin degerlendirilmesine mahsus usul | |
| FI971527L (fi) | Indolijohdannaisten käyttö erilaisten sairauksien hoitoon | |
| AU9173191A (en) | Medicaments for the treatment of papillomavirus diseases | |
| FI930674L (fi) | Terapeutiska aemnen | |
| EE03384B1 (et) | Melatoniini kasutamine ravimi tootmiseks | |
| NO914071D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser | |
| NO991164D0 (no) | Farmas°ytisk preparat for behandling av virussykdommer | |
| BG96715A (bg) | Терапевтични вещества | |
| FI931071L (fi) | Terapeutiska aemnen | |
| NO922315D0 (no) | Sproeyte for tilfoersel av medisin |